Pharmacist • Attorney • Scholar
Pharm.D., J.D., C.P.B.S.
Analysis at the intersection of pharmacy law, PBM regulation, healthcare competition, and reimbursement.
Two disciplines.
One informed perspective.
Independent scholarship
Long-form work is published here in stable, citable form, then shared in concise form through professional channels.
Visit the analysis archiveSelected work
Forthcoming journal work and current research addressing ERISA § 514, PBM network regulation, pharmacy access, antitrust, and health-law federalism.
Forthcoming
Journal of Health Care Law & Policy
An examination of ERISA preemption in relation to PBM regulation and pharmacy competition.
Citation, external link, and authorized manuscript access will be added when available.
Manuscript in revision • 2026
Publication information pending
A manuscript addressing the constitutional conflict surrounding state regulation of pharmacy ownership and the first generation of structural PBM regulation.
Citation, external link, and authorized manuscript access will be added when available.
Analysis
Timely examination of legal, regulatory, and economic developments affecting pharmacies, healthcare intermediaries, and the markets in which they operate.
Each published entry preserves its sources, original publication date, reading time, topic classification, and any later update date.
Open the analysis archiveAreas of inquiry
Legal doctrine, regulatory structure, and pharmacy operations are inseparable. Each topic is treated as part of the same healthcare system.
Network rules, contracting structures, provider manuals, credentialing requirements, and the state and federal laws governing pharmacy participation and accountability.
Market structure, concentration, vertical relationships, and the role of healthcare intermediaries in shaping competition for pharmacies and patients.
ERISA § 514 and the boundary between federal benefits law and state regulation of PBMs, pharmacy networks, reimbursement, and access.
Payment structures, network terms, dispensing economics, and the legal and operational consequences of reimbursement policy.
Pharmacy audits, provider-manual requirements, recoupment disputes, documentation standards, compliance systems, and enforcement.
Legal and operational developments involving 340B and drug-pricing policy across pharmacies, manufacturers, intermediaries, and regulators.
The changing obligations of pharmacists, compliance burdens, operational pressure, professional practice, and sustainable pharmacy access.
About Toby
Dr. Toby C. Frost is an Alabama-admitted attorney, Tennessee-licensed pharmacist, pharmacy founder and former executive, educator, and health-law scholar.
More than twenty years of pharmacy operational and executive experience inform his work on PBM regulation, ERISA preemption, pharmacy competition, reimbursement, audits, and healthcare regulatory design.
Read the full biographyScholarship • Media • Speaking